 adjust estim impact
beyond
messag monday close provid updat expect impact
mitig effort busi updat estim
addit disclosur previous bake anticip impact
viru forecast expect headwind sever driven
expect loss fiscal yearend bulk purchas order walk
key chang model
forecast ep yoy total revenu
cc compar prior estim respect expect
post worst result large-cap med-tech group quarter due
time viru mitig effort peak relat compani fiscal year
quarter includ rel unaffect januari full impact
peak procedur declin april also tend see end quarter bulk
purchas hospit peer dynam expect disrupt hospit
conserv cash find inventori usual due procedur delay
final sale rep everi compani tend push extra hard end fiscal
year tri reach product bonu threshold longer possibl
quarter becom particularli tough comp
model ep cc sale estim
littl chang prior forecast continu monitor data hospit
roundtabl see progress lift state restrict see gaug
slope recoveri look current model ep
pre-covid forecast expect out-year estim group remain
somewhat fluid visibl improv extent demand destruct due linger
sector medic suppli devic
page analyst certif import disclosur
wake covidien merger emerg largest med-tech
compani world boast lead franchis across wide varieti end market
sinc compani work translat unmatch scale competit
advantag strategi yield mix result howev growth
recent year lag behind rest large-cap med-tech group expect
chang longer term pipeline-driven growth acceler narrow perform
gap peer visibl enhanc growth outlook
improv impact becom clearer expect valuat gap
rest large-cap med-tech group close well drive
meaning upsid potenti current level
share current trade ep estim
ebitda discount large-cap med-tech group averag
respect pipelin kick next month see medtron
normal growth acceler top bottom
line respect roughli line broader group averag visibl
improv outlook increas full impact becom clearer
expect stock trade less discount large-cap med-tech peer
maintain price target base multipl
downsid risk rate includ clinic setback weaker-than-expect adopt
new product caus revenu fall short street estim better-than-expect
share gain competitor failur execut margin expans goal
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
million usd
compani report guggenheim secur llc estim
page analyst certif import disclosur
